Skip to main content
    O

    Organogenesis Holdings Inc (ORGO)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $0.80
    -0.01 (-0.86%)

    Market Cap: $105.15M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Organogenesis Holdings Inc (ORGO) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Organogenesis Holdings reported revenue of $564.17M for the fiscal year ended Dec 31, 2025, up 17.0% from the year before. That year, net income was $37.03M with a net margin of 6.6%, operating cash flow was -$10.31M and free cash flow was -$24.46M. The quarter ended Sep 30, 2026 had revenue of $45.46M and net income of -$29.63M.

    Revenue and Margins

    The operating margin was 7.9% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $138.73M, a compound annual rate of 16.9%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$564.17M+17.0%75.6%7.9%6.6%
    Dec 2024$482.04M+11.3%76.0%-0.3%0.2%
    Dec 2023$433.14M-3.9%75.4%2.9%1.1%
    Dec 2022$450.89M-3.5%76.7%4.9%3.4%
    Dec 2021$467.36M+38.2%75.6%15.5%20.2%
    Dec 2020$338.30M+29.6%74.2%7.9%5.1%
    Dec 2019$260.98M+34.9%70.9%-11.4%-14.8%
    Dec 2018$193.45M-2.5%64.4%-26.7%-33.5%
    Dec 2017$198.51M+43.1%69.2%-2.8%-3.8%
    Dec 2016$138.73MN/A65.3%-6.3%-10.6%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income rose 4200.8% from the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$564.17M$482.04M$433.14M$450.89M$467.36M$338.30M$260.98M$193.45M$198.51M$138.73M
    Cost of revenue$137.52M$115.74M$106.48M$105.02M$114.20M$87.32M$75.95M$68.81M$61.22M$48.20M
    Gross profit$426.65M$366.30M$326.66M$345.87M$353.16M$250.98M$185.03M$124.64M$137.29M$90.53M
    Research and development$44.54M$50.27M$44.38M$39.76M$30.74M$20.09M$14.80M$10.74M$9.06M$6.28M
    Operating income$44.69M-$1.28M$12.53M$22.30M$72.22M$26.70M-$29.85M-$51.56M-$5.49M-$8.78M
    Net income$37.03M$861.00K$4.95M$15.53M$94.20M$17.23M-$38.71M-$64.83M-$7.53M-$14.77M
    EBITDA$63.28M$15.76M$27.95M$40.32M$88.88M$37.23M-$17.88M-$44.88M-$912.00K-$1.91M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$45.46M$43.76M$37.23M$225.61M$150.86M$101.00M$86.69M$126.66M$115.18M$130.23M$109.98M$99.65M
    Gross profit$23.56M$20.08M$11.46M$175.69M$114.61M$73.38M$62.97M$95.61M$88.38M$101.04M$81.28M$71.88M
    Operating income-$29.49M-$50.99M-$68.89M$63.29M$20.73M-$12.58M-$26.75M$10.22M$6.24M-$13.89M-$3.85M-$1.27M
    Net income-$29.63M-$96.27M-$53.16M$43.70M$21.57M-$9.39M-$18.84M$7.67M$12.33M-$17.04M-$2.10M-$569.00K
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $4.95M by $88.73M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$598.73M$497.89M$460.02M$449.36M$443.26M$290.22M$220.69M$163.68M$148.72M$311.44M
    Current assets$362.19M$285.94M$225.04M$222.61M$226.98M$174.34M$125.60M$71.13M$49.74M$1.44M
    Cash and equivalents$93.68M$135.57M$103.84M$102.48M$113.93M$84.39M$60.17M$21.29M$2.31M$1.04M
    Total liabilities$164.81M$112.57M$181.36M$183.69M$201.92M$148.41M$165.10M$116.64M$157.28M$11.33M
    Short-term debt$4.95M$0$18.63M$4.54M$14.44M$16.67M$3.06M$9.78M$10.37M$0
    Long-term debt$0$0$60.74M$66.23M$70.77M$53.04M$83.12M$39.06M$84.58M$73.39M
    Shareholder equity$300.13M$262.90M$278.66M$265.67M$241.34M$141.81M$55.58M$47.04M-$15.32M$5.00M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$368.90M$406.45M$519.99M$598.73M$509.83M$461.13M$467.39M$497.89M$446.30M$443.16M$458.48M$460.02M
    Total liabilities$106.16M$118.31M$138.65M$164.81M$123.85M$99.91M$99.33M$112.57M$167.75M$179.66M$180.45M$181.36M
    Cash and equivalents$21.33M$46.10M$91.38M$93.68M$63.74M$73.08M$109.97M$135.57M$94.34M$89.90M$88.63M$104.34M
    Shareholder equity$119.74M$148.27M$244.56M$433.92M$255.13M$233.24M$242.90M$385.32M$278.55M$263.50M$278.03M$278.66M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$10.31M$14.21M$30.92M$24.86M$61.98M$5.47M-$33.53M-$60.63M-$3.49M-$4.87M
    Capital expenditures$14.15M$10.03M$24.36M$33.90M$31.22M$17.68M$5.98M$1.86M$2.43M$1.36M
    Free cash flow-$24.46M$4.18M$6.55M-$9.04M$30.76M-$12.21M-$39.51M-$62.49M-$5.92M-$6.23M
    Dividends paid$11.37M$1.80MN/A$648.00K$1.46MN/A$57.90MN/AN/A$5.20M
    Share repurchases$0$25.48M$0$0$0$5.66M$2.97M$270.00KN/AN/A
    Investing cash flow-$14.15M-$10.03M-$24.36M-$33.90M-$31.22M-$23.50M-$6.23M-$1.86M-$14.87M-$1.25M
    Financing cash flow-$17.36M$27.64M-$5.50M-$2.20M-$1.04M$42.47M$78.73M$81.54M$18.87M$6.78M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$18.59M-$31.65M$21.13M$39.42M$3.08M-$32.87M-$19.93M$10.94M$8.70M$4.74M-$10.16M$10.61M
    Capital expenditures$1.47M$1.10M$3.15M$4.65M$2.23M$3.64M$3.63M$3.36M$2.57M$1.88M$2.22M$3.32M
    Free cash flow-$20.06M-$32.75M$17.98M$34.77M$844.00K-$36.51M-$23.56M$7.58M$6.13M$2.86M-$12.38M$7.29M
    Last 12 quarters

    Frequently Asked Questions About ORGO

    What is Organogenesis Holdings' annual revenue?

    Organogenesis Holdings reported revenue of $564.17M for the fiscal year ended Dec 31, 2025.

    How fast is Organogenesis Holdings' revenue growing?

    Revenue was up 17.0% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 7.8%.

    Is Organogenesis Holdings profitable?

    Yes. Organogenesis Holdings reported net income of $37.03M for the fiscal year ended Dec 31, 2025, with a net margin of 6.6%.

    How much free cash flow does ORGO generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$10.31M minus capital expenditures of $14.15M produced free cash flow of -$24.46M.

    How much debt does Organogenesis Holdings have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $0, short-term debt of $4.95M and cash and equivalents of $93.68M.